We’re scouring the Studies to Bring You Information on How CBD Supports Health
Cannabinoids, also known as CBD, is beginning to trend all over the world. Something that used to be part of our everyday diet since hunter gatherer days, we as a species have managed to remove it over the years. Yet our bodies have have an endocannabanoid system (ECS) that has largely been ignored for the past 100 years.
Recently, we released an article outlining 21 Articles Supporting Medical Claims for Various Maladies. Since then have been receiving an overwhelming amount of requests to please find more. We, at Canna CBD, decided to dig deeper.
It is our purpose to help educate people about the benefits of nature’s amazing gift. We also want to make everyone aware that CBD is not the same as THC, and there are no hallucinogenic properties associated with cannabinoids.
Without further adieu, here are 10 more studies detailing the benefits of CBD.
Antitumor in glial cells
Mentioned in the Journal of Pharmacology and Experimental Therapeutics 1, a study was undertaken to “evaluated the in vitro antiproliferative ability of Cannabidiol”. Through the test on human glioma cells, it was found that “in conclusion, the non psychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent”.
Also taken from the Journal of Pharmacology and Experimental Therapeutics 2, this study claims that Cannabidiol can be used in the treatment of breast cancer. “Results obtained in a panel of tumor cell lines clearly indicate that, of the five natural compounds tested, cannabidiol is the most potent inhibitor of cancer cell growth”. The study itself consisted of using mice and rats.
Following on from the section all about CBD and anxiety, the article mentioned within Volume 213 of Psychopharmacology 3 states how Cannabidiol can affect anxiolytic-like effects. The study itself worked by using rats who were injected by CBD, and then were exposed to “the elevated plus-maze (EPM) or to the Vogel conflict test (VCT). The results of the test found that “CBD increased open arms exploration in the EPM as well as the number of punished licks in the VCT, suggesting an anxiolytic-like effect. And that “These results give further support to the proposal that BNST is involved in the anxiolytic-like effects of CBD observed after systemic administration, probably by facilitating local 5-HT1A receptor-mediated neurotransmission”.
In a study that was mentioned in the Proceedings of the National Academy of Sciences 4, they used mice to test the effect of Cannabidiol on arthritis. They did this by “immunizing DBA/1 mice with type II collagen (CII) in complete Freund’s adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively”. After the relapse, they administered CBD – “after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally”. These results showcase how CBD can be used to help with the condition – both in stopping it progressing and helping as an anti-inflammatory.
A research article that was mentioned on Plos One 5, stated that by using Cannabidiol in a study, it lead to a reduction of intestinal damage mediated by PPARgamma receptor pathway. Our results therefore indicate that CBD indeed unravels a new therapeutic strategy to treat inflammatory bowel diseases”. The study itself used 18 people in an experiment, that went for a colon cancer screening.
A study mentioned in Molecular Cancer Therapeutics 6 stated that it “revealed an intricate interplay between apoptosis and autophagy in CBD-treated breast cancer cells and highlighted the value of continued investigation into the potential use of CBD as an antineoplastic agent”. This statement, which is also made by others across the web show how CBD can be used to kill breast cancer cells.
Another article featured on Molecular Cancer Therapeutics 7 shows how Cannabidiol can be used to help with tumour aggressiveness. The results of which found that “CBD represents the first nontoxic exogenous agent that can significantly decrease Id-1 expression in metastatic breast cancer cells leading to the down-regulation of tumor aggressiveness”.
In a case report posted on Wiley Online Library 8, it stays how Cannabidiol can be used to help with cannabis withdrawal. An addiction which is mentioned in the addiction section above, the study showed how a 19-year-old woman who suffered from withdrawal syndrome used CBD. Testing her anxiety and other symptoms, it concluded that “CBD can be effective for the treatment of cannabis withdrawal syndrome”. To find out more, you can read the whole article through the cited link.
Autism is a condition that is faced by millions. Recent research reported on Arutz Sheva has claimed that by using CBD, “80% of the children’s parents who participated in the study reported a decrease in problematic behavior, with 62% per cent reporting that their child’s behavior improved significantly.” 9 This impressive figure is convincing many around the globe to test CBD out. It should, however, be something that you should check with your child’s doctor or your own if you are suffering with it first.
Quality of Life for Seniors
Recently there have been reports globally that CBD can be used to improve the lives of senior citizens. A report on Forbes 10 claims that “ A recent study of 1,000 seniors ages 54 and up by Remedy Review found that 9% of seniors have tried CBD for health-related reasons and 51% of those that have tried it reported having an improved quality of life afterward. Over 65% of the seniors surveyed that tried CBD said that their quality of life was good, while only 31.1% said the same before trying CBD.” This statistic, of course, is a generalisation based on one small percentage. But the results are definitely positive.
Do you have a personal story to tell? We’d love to connect and publish your story on our website. Please contact email@example.com with the subject line: My CBD Story. We will need your contact info, since all our stories will be verified.
- Massi, P., Vaccani, A. Ceruti, S, Colombo, A, Abbracchio, M.P and Parolara, D Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines (2004) featured in the Journal of Pharmacology and Experimental Therapeutics http://jpet.aspetjournals.org/content/308/3/838.short
- Various authors, Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma (2006), featured in the Journal of Pharmacology and Experimental Therapeutics http://jpet.aspetjournals.org/content/318/3/1375.short
- Gomes, F.V., Resstel, L.B.M. & Guimarães, F.S. Psychopharmacology (2011) 213: 465 https://link.springer.com/article/10.1007/s00213-010-2036-z
- A. M. Malfait, R. Gallily, P. F. Sumariwalla, A. S. Malik, E. Andreakos, R.Mechoulam, M. Feldmann, Proceedings of the National Academy of Sciences Aug 2000, 97 (17) 9561-9566; https://www.pnas.org/content/97/17/9561.abstract
- Various authors, Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (2011),Plos One – https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0028159
- Shrivastava, A., Kuzontkoski, P.M, Groopman, J.E and Prasad, A Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy (2011), Molecular Cancer Therapeutics, http://mct.aacrjournals.org/content/10/7/1161.short
- McAllister, S. D, Christian, R.T, Horowitz, M.P, Garcia, A. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells (2007) http://mct.aacrjournals.org/content/6/11/2921.short
- J. A. S. Crippa MD, PhD J. E. C. Hallak MD, PhD J. P. Machado‐de‐Sousa PhD R. H. C. Queiroz PhD M. Bergamaschi PhD M. H. N. Chagas MD, MSc A. W. Zuardi MD, PhD – Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report (2012), https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.12018